John Hall PhD is Vice President for Research and Development at Molecular International Research and Director of Research at The Beljanski Foundation. Dr. Hall was a Graduate Fellow at Princeton University, in the Department of Biochemical Sciences, and he completed his PhD at New York University, in the Department of Biochemistry.

Dr. Hall was a Postdoctoral Fellow at Rockefeller University, in Cell Biology. He was promoted to the faculty, where his research focused on microtubule organizing centers and microtubule organelle assembly.

He has presented scientific lectures all over the United States and in Europe, including: the American Society of Cell Biology, the National Cancer Institute, the Environmental Protection Agency, Memorial Sloan-Kettering Cancer Center, Johns Hopkins University, the Salk Institute, Rockefeller University, the American Academy of Anti-Aging Medicine, the Cancer Control Society, Integrative Oncology Conference, and CAM for Cancer – Complementary and Alternative Medicine Conference.  He served as President and CEO of Motility Research Corporation.

He has three successful patent applications, one for ‘Prevention and Treatment of Prostate Cancer’ (US and PCT), a second for ‘Therapeutic Treatments Based on Administration of Small RNA Fragments’ (EU, Japan, and India), and the latest ‘Selective Anti-cancer Agent Effective for Prevention and Treatment’ (US and EU, Pending in Canada, China, and Japan).